Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: Influence of tumor subtypes

Annals of Oncology

Volumn 23, Issue 10, 2012, Pages 2572-2577

  Humbert, O ^a   Berriolo Riedinger, A ^a   Riedinger, J M ^a   Coudert, B ^a   Arnould, L ^a   Cochet, A ^a,b   Loustalot, C ^a   Fumoleau, P ^a,b   Brunotte, F ^a,b  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Breast cancer subtype; FDG PET; Immunohistochemistry; Monitoring therapy; Neoadjuvant chemotherapy

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; PROGESTERONE RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CLASSIFICATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METABOLISM;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY;

EID: 84867124040     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds071     Document Type: Article

References (45)

1. Gralow JR, Burstein HJ, Wood W et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008; 26: 814-819.
2. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 188-194.
3. Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
4. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
5. Kim SJ, Kim SK, Lee ES et al. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2004; 15: 1352-1357.
6. Schwarz-Dose J, Untch M, Tiling R et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol 2009; 27: 535-541.
7. Berriolo-Riedinger A, Touzery C, Riedinger JM et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007; 34: 1915-1924.
8. Rousseau C, Devillers A, Sagan C et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F] fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006; 24: 5366-5372.
9. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685.
10. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-10874.
11. Bhargava R, Beriwal S, Dabbs DJ et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer 2010; 116: 1431-1439.
12. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with longterm follow-up. Histopathology 2002; 41: 154-161.
13. Bonneterre J, Roche H, Kerbrat P et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2005; 23: 2686-2693.
14. Roche H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24: 5664-5671.
15. Bonnefoi H, Potti A, Delorenzi M et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2007; 8: 1071-1078.
16. Fumoleau P, Cameron D. Future options with capecitabine (Xeloda) in (neo) adjuvant treatment of breast cancer. Semin Oncol 2004; 31: 45-50.
17. Coudert BP, Largillier R, Arnould L et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 2007; 25: 2678-2684.
18. Coudert BP, Arnould L, Moreau L et al. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 2006; 17: 409-414.
19. Chevallier B, Roche H, Olivier JP et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993; 16: 223-228.
20. Zafrani B, Aubriot MH, Mouret E et al. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology 2000; 37: 536-545.
21. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
22. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502.
23. de Ronde JJ, Hannemann J, Halfwerk H et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 2010; 119: 119-126.
24. Specht JM, Kurland BF, Montgomery SK et al. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res 2010; 16: 2803-2810.
25. Schmidt FH. [Blood glucose levels in capillary blood of adults assessed by the hexokinase method (author's transl)]. Klin Wochenschr 1973; 51: 520-522.
26. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
27. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100: 8418-8423.
28. rb-Esfahani S, Loibl S, Muller BM et al. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res 2009; 11: R69.
29. Colleoni M, Viale G, Zahrieh D et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004; 10: 6622-6628.
30. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329.
31. Groheux D, Giacchetti S, Moretti JL et al. Correlation of high (18)F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 2011; 38: 426-435.
32. Mavi A, Cermik TF, Urhan M et al. The effects of estrogen, progesterone, and CerbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med 2007; 48: 1266-1272.
33. Osborne JR, Port E, Gonen M et al. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis. J Nucl Med 2010; 51: 543-550.
34. Basu S, Chen W, Tchou J et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 2008; 112: 995-1000.
35. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
36. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334.
37. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
38. Schneider-Kolsky ME, Hart S, Fox J et al. The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET. Breast Cancer Res 2010; 12: R37.
39. Arnould L, Gelly M, Penault-Llorca F et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer 2006; 94: 259-267.
40. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
41. Berruti A, Brizzi MP, Generali D et al. Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions. Oncologist 2008; 13: 1137-1148.
42. de Ronde JJ, Hannemann J, Halfwerk H et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 2010; 119: 119-126.
43. Dunnwald LK, Doot RK, Specht JM et al. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. Clin Cancer Res 2011; 17: 2400-2409.
44. Boellaard R, Oyen WJ, Hoekstra CJ et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008; 35: 2320-2333.
45. Boellaard R. Need for standardization of 18F-FDG PET/CT for treatment response assessments. J Nucl Med 2011; 52 (Suppl 2): 93S-100S.